Compare PAY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAY | ADPT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.7B |
| IPO Year | 2021 | 2019 |
| Metric | PAY | ADPT |
|---|---|---|
| Price | $31.49 | $22.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $36.29 | $17.78 |
| AVG Volume (30 Days) | 902.7K | ★ 2.7M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.57 | ★ 63.89 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $1,196,507,000.00 | $276,976,000.00 |
| Revenue This Year | $18.60 | $3.98 |
| Revenue Next Year | $18.89 | $22.72 |
| P/E Ratio | $196.75 | ★ N/A |
| Revenue Growth | 37.25 | ★ 54.77 |
| 52 Week Low | $20.11 | $9.96 |
| 52 Week High | $39.38 | $23.15 |
| Indicator | PAY | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.80 | 61.02 |
| Support Level | $28.13 | $15.08 |
| Resistance Level | $32.07 | $22.97 |
| Average True Range (ATR) | 1.11 | 1.26 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 98.80 | 80.17 |
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.